Genprex (NASDAQ:GNPX) Stock Falls 0.4% – Here’s Why

Genprex (NASDAQ:GNPX) traded down 0.4% during trading on Monday. The company traded as low as $2.16 and last traded at $2.23. 241,574 shares traded hands during trading, an increase of 27% from the average daily volume of 190,479 shares. The stock had previously closed at $2.24.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Genprex Stock Performance

The stock’s fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $20.55. The company has a market capitalization of $1.83 million, a price-to-earnings ratio of -0.02 and a beta of -0.99.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($9.40) earnings per share (EPS) for the quarter.

About Genprex

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles.

Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies.